What is Nicox?
Founded in 1996 and headquartered in Sophia Antipolis, France, Nicox is dedicated to advancing treatments for prevalent eye conditions such as open-angle glaucoma, ocular hypertension, and dry eye disease. The company has successfully brought to market key products like VYZULTA and ZERVIATE, which are licensed to global partners. Nicox's operations span Europe and North America, underpinned by a robust commitment to scientific research in the ophthalmology sector. Its public trading on Euronext Paris and inclusion in various healthcare indices highlight its established presence in the pharmaceutical and biotech landscape.
How much funding has Nicox raised?
Nicox has raised a total of $58.7M across 4 funding rounds:
Share Placement
$13.6M
Share Placement
$18.2M
Share Placement
$16.9M
Share Placement
$10M
Share Placement (2019): $13.6M with participation from Undisclosed
Share Placement (2020): $18.2M led by HBM Healthcare Investments
Share Placement (2021): $16.9M, investors not publicly disclosed
Share Placement (2022): $10M, investors not publicly disclosed
Key Investors in Nicox
HBM Healthcare Investments
HBM Healthcare Investments is a publicly traded investment company focused on the global healthcare sector, with a diversified portfolio of private and publicly listed companies. The firm aims to capitalize on the significant growth opportunities within the healthcare market, driven by demographic trends, medical advancements, and increasing demand for innovative therapies. HBM Healthcare Investments offers attractive returns, with a historical dividend yield of 3 to 5 percent per year. Their investment strategy emphasizes the potential for value creation in a rapidly evolving industry.
What's next for Nicox?
The substantial enterprise-level investment positions Nicox for accelerated growth and further research and development initiatives. This strategic capital infusion is expected to bolster the company's pipeline, potentially leading to the expansion of its product portfolio and market reach. Nicox is poised to leverage this financial backing to solidify its leadership in the ophthalmology space, driving innovation in ocular health treatments and enhancing patient outcomes globally.
See full Nicox company page
